Strand Therapeutics
Daniel Dzurko holds a Bachelor of Science in Biochemistry from The University of Texas at Austin and has extensive experience in analytical development within the biotechnology sector. Currently an Associate Director at Strand Therapeutics since August 2021, Daniel has previously served in various scientific roles at Oncorus and bluebird bio, focusing on lentiviral vector characterization and regulatory compliance. Notable achievements include driving data collection for regulatory submissions, overseeing stability data generation, and designing experiments to understand vector degradation. Earlier experience at BioReliance involved developing assays for viral gene therapy vectors and executing GMP/GLP assays for viral adventitious agents. Daniel's career initiated with a role as a Certified Pharmacy Technician at Walgreens and includes research experience at The University of Texas at Austin, where innovative drug inhibitors for Leishmania major were discovered.
This person is not in any teams
This person is not in any offices
Strand Therapeutics
3 followers
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics.